Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study

HIV disease, metabolic dysfunction and atherosclerosis: A three year prospective study

(2019) Hann Low et al.   PLoS One

No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up

(2019) Leonardo Calza et al.   Infectious Diseases

Burden of subclinical carotid atherosclerosis and vascular risk factors among people living with HIV in Ghana

(2018) Fred Stephen Sarfo et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Brief Report

(2017) Bernard J. Macatangay et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Association of Macrophage Inflammation Biomarkers With Progression of Subclinical Carotid Artery Atherosclerosis in HIV-Infected Women and Men

(2017) David B. Hanna et al.   JOURNAL OF INFECTIOUS DISEASES

HIV infection as vascular risk: A systematic review of the literature and meta-analysis

(2017) Jose Gutierrez et al.   PLoS One

Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection

(2016) Theodoros Kelesidis et al.   AIDS

Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s

(2016) Theodoros Kelesidis et al.   ANTIVIRAL THERAPY

Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection

(2016) Irini Sereti et al.   CLINICAL INFECTIOUS DISEASES

Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection

(2016) Peter W. Hunt et al.   JOURNAL OF INFECTIOUS DISEASES

Lipid Abnormalities and Inflammation in HIV Inflection

(2016) Nicholas T. Funderburg et al.   Current HIV/AIDS Reports

A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness

(2015) James H. Stein et al.   AIDS

The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation

(2015) Nikolas Itaru Wada et al.   AIDS

Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks

(2015) Romina Quercia et al.   CLINICAL DRUG INVESTIGATION

Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s

(2015) Theodoros Kelesidis et al.   CLINICAL INFECTIOUS DISEASES

Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy

(2015) S Hattab et al.   HIV MEDICINE

Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation

(2015) David A. Zidar et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Rate and predictors of carotid artery intima media thickness progression in antiretroviral-naive HIV-infected and uninfected adults: a 48-week matched prospective cohort study

(2013) Corrilynn O Hileman et al.   ANTIVIRAL THERAPY

Effect of Improving Glycemic Control in Patients With Type 2 Diabetes Mellitus on Low-Density Lipoprotein Size, Electronegative Low-Density Lipoprotein and Lipoprotein-Associated Phospholipase A2 Distribution

(2012) José L. Sánchez-Quesada et al.   AMERICAN JOURNAL OF CARDIOLOGY

Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients

(2012) Randa Bittar et al.   ANTIVIRAL THERAPY

Asymmetric dimethylarginine concentrations decrease in patients with HIV infection under antiretroviral therapy

(2012) Katharina Kurz et al.   ANTIVIRAL THERAPY

LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy

(2012) Maria Saumoy et al.   ATHEROSCLEROSIS

Small dense LDL: An emerging risk factor for cardiovascular disease

(2012) Satoshi Hirayama et al.   CLINICA CHIMICA ACTA

HIV Infection and Coronary Heart Disease: An Intersection of Epidemics

(2012) Virginia A. Triant   JOURNAL OF INFECTIOUS DISEASES

Biomarkers of Microbial Translocation and Macrophage Activation: Association With Progression of Subclinical Atherosclerosis in HIV-1 Infection

(2012) Theodoros Kelesidis et al.   JOURNAL OF INFECTIOUS DISEASES

Grosor íntima-media carotídeo en población española: valores de referencia y asociación con los factores de riesgo cardiovascular

(2012) Maria Grau et al.   REVISTA ESPANOLA DE CARDIOLOGIA

Small Dense Lipoproteins, Apolipoprotein B, and Risk of Coronary Events in HIV-Infected Patients on Antiretroviral Therapy

(2011) Heiner C. Bucher et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Soluble CD163, a Novel Marker of Activated Macrophages, Is Elevated and Associated With Noncalcified Coronary Plaque in HIV-Infected Patients

(2011) Tricia H. Burdo et al.   JOURNAL OF INFECTIOUS DISEASES

Carotid-Wall Intima–Media Thickness and Cardiovascular Events

(2011) Joseph F. Polak et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIV, HAART, and lipoprotein particle concentrations in the Womenʼs Interagency HIV Study

(2010) Phyllis C Tien et al.   AIDS

Antiretroviral Therapy is Associated With an Atherogenic Lipoprotein Phenotype Among HIV-1-Infected Men in the Multicenter AIDS Cohort Study

(2009) Sharon A Riddler et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection

(2008) Milena Maria Moreira Guimarães et al.   ATHEROSCLEROSIS